Clinical Trial Update: A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma [Phase 2]

View source ↗

Summary

This document reports the withdrawal of a Phase II trial evaluating the combination of sunitinib and nivolumab for KIT-mutated advanced melanoma. The sponsor is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• OPDIVO (nivolumab)
• Sutent (sunitinib)

Snippet

Sponsor: California Pacific Medical Center Research Institute | Conditions: Melanoma | Phase 2 | Status: WITHDRAWN